Figure 715

Interferon in HCV-positive end-stage renal disease (ESRD) and transplant patients. aInterferon therapy in patients infected with hepatitis C virus (HCV) who have ESRD has been studied in both patients receiving dialysis and transplantation recipients. Some studies have reported encouraging early responses [107-111]. Relapses are common after cessation of treatment, however, and many transplantation recipients have experienced deterioration in allograft function [112-116]. Based on the poor outcomes reported in transplantation recipients, additional studies are needed. These studies would evaluate the long-term benefits of a strategy in which infected patients who have ESRD are treated with a-interfer-on while on dialysis in an effort to clear viremia before the planned transplantation. Further study of protocols using extended treatment periods coupled with differing dosing regimens are necessary to determine the optimal therapy for the patient infected with HCV who has ESRD.

0 0

Post a comment